In this episode of the Heart Failure Beat, our hosts sit down with Dr. James Fang, immediate past president of the Heart Failure Society of America, to discuss highlights from his term and the advancements shaping heart failure care. Dr. Fang reflects on major scientific breakthroughs, including the SEQUOIA-HCM and FINEARTS-HF trials, and the role of GLP-1 agonists. He also emphasizes the societal importance of accessible treatments, especially with recent legislative changes impacting drug affordability. Dr. Fang highlights initiatives like the Heart Failure Research Foundation’s support for early-career investigators and the Journal of Cardiac Failure's expansion into Open Access, which together aim to foster collaboration and drive innovation. Tune in for insights on pivotal developments, the future of heart failure as a specialty, and the Society’s commitment to fostering a multidisciplinary approach to patient care.

In this episode of Heart Failure Beat, Priya and Michael interview Dr. Partho Sengupta – cardiology artificial intelligence (AI) aficionado – who shares his expertise on the role of AI in transforming cardiovascular care, from diagnostics to personalized treatment. On Heart Failure Rounds, Michael discusses the latest research on nurse-led titration clinics and their significant impact on heart failure rehospitalizations and mortality. The episode wraps up with Priya’s review of the latest trials presented at the European Society of Cardiology (ESC), highlighting new therapies and breakthroughs in cardiac and kidney care on From Failure to Function. A must-listen for clinicians interested in cutting-edge heart failure management.

On the July episode of the Heart Failure Beat, we celebrate the graduation of newly-minted advanced heart failure and transplant cardiologists. Michael and Priya welcome doctors Matthew Colna, Lekha Racharla, Benjamin Stoner, and Anas Jawaid to reflect on their PGY-7 year and look ahead on their first year as cardiology attendings. The EFFORT and CAST-HF trials, Arrhythmia-Induced Cardiomyopathy, and a Randomized Trial of Cholesterol Lowering With Evolocumab are also discussed.